| Literature DB >> 35268328 |
Alexander Meyer1, Evgenia Boxberger1, Christian-Alexander Behrendt2, Shatlyk Yagshyyev1, Irina Welk1, Werner Lang1, Ulrich Rother1.
Abstract
(1) Background: While tibial bypass surgery still plays a role in the treatment of patients with chronic limb-threatening ischemia and diabetic foot syndrome; only a few centers have recorded considerable numbers of these conditions. The current study aimed to determine contemporary practice with special focus on the performance of extra-anatomic grafting to the infrapopliteal arteries. (2)Entities:
Keywords: CLTI; extra-anatomic bypass reconstruction; prosthetic bypass grafts; tibial bypass surgery
Year: 2022 PMID: 35268328 PMCID: PMC8911520 DOI: 10.3390/jcm11051237
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Patients and periprocedural characteristics and comparison of the distribution between the anatomic and extra-anatomic bypass groups.
| Patients Characteristics | Total N (%) | Anatomic Bypass | Extra-Anatomic Bypass | |
|---|---|---|---|---|
| Arterial hypertension | 412 (90.5) | 365 (80.2) | 47 (10.3) | 0.804 |
| Diabetes | 229 (50.3) | 208 (45.7) | 21 (4.6) | 0.183 |
| Coronary artery disease | 244 (53.6) | 218 (47.9) | 26 (5.7) | 0.766 |
| Hyperlipidemia | 223 (49.0) | 195 (42.9) | 28 (6.2) | 0.616 |
| Smoking (currently and formal) | 255 (56.0) | 227 (49.9) | 28 (6.2) | 0.774 |
| Dialysis dependency | 25 (5.5) | 22 (4.8) | 3 (0.6) | 0.904 |
|
| ||||
| Acute limb ischemia (as indication for bypass surgery) | 53 (11.6) | 45 (9.8) | 8 (1.7) | 0.353 |
| Rutherford Stage | 0.06 | |||
| 3 | 29 (6.3) | 24 (5.3) | 4 (0.09) | |
| 4 | 57 (12.5) | 47 (10.3) | 10 (2.2) | |
| 5/6 | 316 (69.5) | 285 (62.6) | 31 (6.8) | |
| Prosthetic bypass grafts | 131 (28.8) | 80 (17.6) | 51 (11.2) | <0.001 |
| Bypass anatomy | 455 (100.0) | 404 (88.7) | 51 (11.2) | |
| WIFI Score amputation risk | 0.451 | |||
| Very low | 9 (2.0) | 9 (2.0) | 0 (0.0) | |
| Low | 76 (16.7) | 63 (13.8) | 13 (2.9) | |
| Moderate | 90 (19.8) | 81 (17.7) | 9 (1.9) | |
| High | 127 (27.9) | 113 (24.8) | 14 (3.1) | |
| Not assessable | 153 (33.6) | 135 (29.7) | 26 (5.7) | |
| No antithrombotic therapy | 12 (2.6) | 9 (1.9) | 3 (0.7) | 0.091 |
| Single antiplatelet therapy | 218 (47.9) | 194 (42.6) | 24 (5.3) | |
| Dual antiplatelet therapy | 46 (10.1) | 41 (9.0) | 5 (1.1) | |
| Vitamin K antagonist | 119 (26.2) | 106 (23.3) | 13 (2.9) | |
| Direct oral anticoagulation | 39 (8.6) | 36 (7.9) | 3 (0.7) | |
| Aspirin and direct oral anticoagulation | 5 (1.1) | 3 (0.7) | 2 (0.4) | |
| Aspirin and Vitamin K antagonist | 14 (3.1) | 13 (2.9) | 1 (0.2) | |
| Triple Therapy | 2 (0.4) | 2 (0.4) | 0 (0.0) |
WIfI: Wound Ischemia foot Infection Score.
Figure 1Comparison of the patency between prosthetic and venous bypass grafts (log-rank p < 0.001).
Figure 2Comparison of the limb salvage rates depending on different bypass materials (log-rank p < 0.001).